Ετικέτες

Πέμπτη 27 Ιουλίου 2017

Using a worldwide in-app survey to explore sugammadex usage patterns: a prospective observational study

Editor—Via encapsulation, sugammadex can rapidly and completely reverse even profound neuromuscular block induced by rocuronium or vecuronium, which is not possible to achieve with cholinesterase inhibitors.1–4 Although approved for use in Europe in 20085 and available for several years elsewhere,6 the United States Food and Drug Administration (US FDA) delayed approval due to concerns regarding potential hypersensitivity reactions and effects on coagulation tests,7 which were ultimately satisfied.8–10 We are interested in better understanding global experience with sugammadex and the impact, if any, of pharmacoeconomics on post-marketing policies. The present data were analysed from an ongoing, Institutional Review Board (IRB)-approved (Emory University, Atlanta, GA, USA, IRB# 00082571) study of a globally utilized anaesthesia calculator app for the Android platform ('Anesthesiologist')1112 fitted with a module capable of collecting survey data and app analytics.13 We used this tool to deploy a survey assessing global patterns of clinical practice and experience with sugammadex.

http://ift.tt/2eRSfNJ

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αναζήτηση αυτού του ιστολογίου